Monkeypox is the newest worldwide pandemic and closely mirrors both COVID-19 and HIV pandemics. A large difference is theoretical vaccines and treatments for monkeypox already exist. In this episode of GameChangers, host Geoff Wall, evaluates tecovirimat, a potential monkeypox treatment and the regulations that made it possible.

The GameChanger
Little to no randomized controlled data exist on tecovirimat’s safety and efficacy in monkeypox. A recent case series helps establish the safety of tecovirimat for monkeypox use.

Show Segments 
00:00 - Introductions
02:40 - Current Issue of Monkeypox
04:02 - Tecovirimat “Animal Rule”
11:19 - The GameChanger: Tecovirimat Case Series
17:20 - Applying to Practice
20:45 - Closing Remarks

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and resources:

• Tecovirimat and the Treatment of Monkeypox - Past, Present, and Future Considerations.
• Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection.

Redeem your CPE or CME credit

• CPE (Pharmacist)
• CME (Physician)

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership 

Continuing Education Information:
Learning Objectives:
1. Describe the development and use of tecovirimat under the “Animal Rule”
2. Discuss the latest report of tecovirimat use in US patients with monkeypox

All relevant financial relationships have been mitigated. 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-354-H01-P
Initial release date: 09/26/22
Expiration date: 09/26/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram